As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.
Among all the regional markets for immunoglobulin, North America accounted for the largest share of the global market. This trend is expected to be maintained over the forecast period due to the hefty expenditure in the healthcare sector facilitating rapid development for antibody therapy. The market in the region witnessed a peak rise during the onset of the coronavirus pandemic, with all the stakeholders conducting over 50 various clinical trials using antibody therapy. Additionally, presence of the several plasma production facilities in the region is a significant factor responsible for propelling the market growth.
Immunoglobulins are administered to patients via the intravenous and subcutaneous routes. The market share occupied by the intravenous segment is a few folds larger than that of the subcutaneous segment. This can be attributed to the high availability of products in this segment and rapid absorption in the patient body during treatment. Intravenous mode of delivery is expected to continue the growth trend in the coming years, aided by several approvals for Intravenous Immunoglobin (IVIg) over the years. Furthermore, hypogammaglobulinemia is estimated to occupy a major share in the global market owing to the noteworthy rise in the prevalence of the associated disorder in recent years.
In September 2020, Biotest AG (ETR: BIO) announced the completion of its study involving 67 patients, including 18 children, for the investigation of IgG Next Generation as replacement therapy in patients diagnosed with primary immunodeficiency disease (PID), a group of disorders in which a part of the body's immune system does not function properly. Moreover, in November 2020, Eli Lilly and Company (NYSE: LLY), an American pharmaceutical company, received emergency use authorisation from the Food and Drug Administration (U.S.A.) for the neutralising antibody bamlanivimab (LY-CoV555). These developments in the industry are expected to further the market growth over the forecast period.
Market Analysis by Application, Route of Administration, Clinical Trial, and Region:
Key Findings of the Report:
Key Offerings of the Report:
The major players in the global immunoglobulin market are Biotest AG, Octapharma AG, Baxter International Inc., China Biologics Products Inc., and Grifols SA, among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.
Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.
EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.
Expert Market Research
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.